Prodrugs pp 1241-1249 | Cite as

Case Study: Fosamprenavir: A Prodrug of Amprenavir

  • Hui Ouyang
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

Fosamprenavir (Lexiva®) is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir (Agenerase®). Amprenavir is a white-to-cream-colored solid with a solubility of approximately 0.04 mg/mL in water at 25°C. It was originally marketed as an oral solution at a concentration of 15 mg/mL that included a variety of excipients, such as acesulfame potassium, artificial grape bubblegum flavor, citric acid, TPGS, menthol, natural peppermint flavor, polyethylene glycol 400, propylene glycol, saccharin sodium, sodium chloride, and sodium citrate (GlaxoSmithKline, 2004). Because the recommended amprenavir regimen is 1200 mg twice daily (equal to 80 mL b.i.d.), the large amount of excipients (propylene glycol in particular) in the oral solution posed potential toxicity problems and prohibited its usage in infants and children under the age of 4 years and in certain other patient populations. Amprenavir is also formulated as capsules in strengths of 50 and 150 mg (GlaxoSmithKline, 2002). The content of vitamin E as TPGS in amprenavir capsules (daily dose of 1744 IU) far exceeds the Reference Daily Intake (adults 30 IU, pediatrics 10 IU). Patients are advised not to take additional vitamin E. To reduce the excipient intake and the burden of 8 capsules twice daily, fosamprenavir was designed as a more watersoluble prodrug (0.31 mg/mL in water at 25°C) of amprenavir (Gatell, 2001), which required only two tablets twice a day.

Keywords

Propylene Glycol Isopropyl Ester Saccharin Sodium Colloidal Silicon Dioxide Vertex Pharmaceutical 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armitage IG, Searle AD, and Singh H. Calcium (3S)-etrahydro-3-furyl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphoroxy) propylcarbamate. PCT Int Appl #2000004033 (Jan. 27) 2000Google Scholar
  2. Corbett AH, and Kashuba ADM. Fosamprenavir Vertex Pharmaceuticals/ GlaxoSmithKline. Curr Opin Invest Drugs 2002; 3:384–390Google Scholar
  3. Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, and Prince WT. Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers. J Clin Pharm 2002; 42:887–898CrossRefGoogle Scholar
  4. Fleisher D, Johnson KC, Stewart BH, and Amidon GL. Oral Absorption of 21-Corticosteroid Esters: a Function of Aqueous Stability and Intestinal Enzyme Activity and Distribution. J Pharm Sci 1986; 75:934–939PubMedCrossRefGoogle Scholar
  5. Fleisher D, Bong R, and Stewart BH. Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs. Adv Drug Deliv Rev 1996; 19:115–130CrossRefGoogle Scholar
  6. Gatell JM. From Amprenavir to GW433908. J HIV Therapy 2001; 6:95–99Google Scholar
  7. GlaxoSmithKline. Product Package Insert for Agenerase Capsules. 2002; http://us.gsk.com/products/assets/us_agenerase_capsules.pdfGoogle Scholar
  8. GlaxoSmithKline. Product Package Insert for Lexiva. 2003; http://us.gsk.com/products/assets/us_lexiva.pdfGoogle Scholar
  9. GlaxoSmithKline. Product Package Insert for Agenerase Oral Solution. 2004; http://us.gsk.com/products/assets/us_agenerase.pdfGoogle Scholar
  10. Hale MR, Tung RD, Baker CT, Spaltenstein A, Furfine ES, Kaldor I, and Kazmierski WM. Preparation of 1,3-Diacylamino-2-acyloxypropanes as Prodrugs of Aspartyl Protease Inhibitors. PCT Int Appl #9933793 (July 8) 1999Google Scholar
  11. Havens PL. Principles of Antiretroviral Treatment of Children and Adolescents with Human Immunodeficiency Virus Infection. Semin Pediatr Infect Dis 2003; 14:269–285PubMedCrossRefGoogle Scholar
  12. Heimbach T, Oh DM, Li LY, Forsberg M, Savolainen J, Leppanen J, Matsunaga Y, Flynn G, and Fleisher D. Absorption Rate Limit Considerations for Oral Phosphate Prodrugs. Pharm Res 2003; 20:848–856PubMedCrossRefGoogle Scholar
  13. McDade HB, Smiley ML, and St. Clair MH. Synergistic Antiviral Combinations Comprising (s)-2-Ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic Acid Isopropyl Ester. PCT Int Appl #2000018384 (Apr. 6) 2000Google Scholar
  14. Park-Wyllie LY, and Phillips EJ. Challenges of Adherence Management in Human Immunodeficiency Virus Pharmacotherapy. Can J Clin Pharmacol 2003; 10:189–195PubMedGoogle Scholar
  15. Sorbera LA, Martin L, Castaner J, and Castaner RM. Fosamprenavir. Anti-HIV HIV Protease Inhibitor. Drugs of the Future 2001; 26:224–231CrossRefGoogle Scholar
  16. Stewart BH, Amidon GL, and Brabec RK. Uptake of Prodrugs by Rat Intestinal Mucosal Cells: Mechanism and Pharmaceutical Implications. J Pharm Sci 1986; 75:940–945PubMedCrossRefGoogle Scholar
  17. Tung RD. Preparation of Tetrahydrofuran-containing Sulfonamide Inhibitors of Aspartyl Protease for Treatment of HIV Infection. PCT Int Appl #9633184 (Oct. 24) 1996Google Scholar
  18. Tung RD and Bhisetti GR. Preparation of Oxygen-heterocyclyl N-(Sulfonamidohydroxyalkyl)carbamates and Analogs as Aspartyl Protease Inhibitors. PCT Int Appl #9633187 (Oct. 24) 1996Google Scholar
  19. Tung RD, Murcko MA, and Bhisetti GR. Preparation of Sulfonamide Inhibitors of Aspartyl Protease. US Patent #5585397 (Dec. 17) 1996Google Scholar
  20. Tung RD, Hale MR, Baker CT, Furfine ES, Kaldor I, Kazmierski WW, and Spaltenstein A. Preparation of Amprenavir Prodrugs as HIV Protease Inhibitors. PCT Int Appl #9933815 (July 8) 1999Google Scholar
  21. Tung RD, Livingston DJ, Rao BG, Kim EE, Baker CT, Boger JS, Chambers SP, Deininger DD, Dwyer M, Elsayed L, Fulghum J, Li B, Murcko MA, Navia MA, Novak P, Pazhanisamy S, Stuver C, and Thomson JA. Design and Synthesis of Amprenavir, a Novel HIV Protease Inhibitor. Infect Disease and Therap 2002; 25:101–118Google Scholar
  22. Wood R, Arasteh K, Stellbrink H-j, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, and Naderer OJ. Six-week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob Agents Chemother 2004; 48:116–123PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Hui Ouyang
    • 1
  1. 1.Department of Pharmaceutical ChemistryThe University of KansasLawrenceUSA

Personalised recommendations